Early clinical trials have yielded encouraging signals (e.g., anti-CD19/CD7 programs for leukemia and BCMA-directed products for myeloma), but autologous CAR-T remains the most practical and clinically validated option at present 31-33. Here, CD19 is linked to leukemia.